We serve Chemical Name:ccpa CAS:37739-05-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:ccpa
CAS.NO:37739-05-2
Synonyms:2-Chloro-N-cyclopentyladenosine;2-Chloro-N6-cyclopentyladenosine;2-Chloro-N6-cyclopentyladenosine,2-Chloro-N-cyclopentyladenosine
Molecular Formula:C15H20ClN5O4
Molecular Weight:369.80300
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:617.3ºC at 760mmHg
Density:1.87g/cm3
Index of Refraction:1.824
PSA:125.55000
Exact Mass:369.12000
LogP:0.51870
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 2-Chloro-N-cyclopentyladenosine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Chloro-N6-cyclopentyladenosine,2-Chloro-N-cyclopentyladenosine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Chloro-N-cyclopentyladenosine Use and application,2-Chloro-N6-cyclopentyladenosine,2-Chloro-N-cyclopentyladenosine technical grade,usp/ep/jp grade.
Related News: Its approval has since been called into question, however, and the head of the FDA is now calling for a federal investigation looking into interactions between agency staff and the biotech company. 4-(3,5-dioxo-1,2-diphenyl-pyrazolidin-4-yl)-benzenesulfonic acid manufacturers RELATED: With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO 2-[2-[dodecanoyl(2-hydroxyethyl)amino]ethylamino]acetic acid suppliers Jan Vertommen, Senior Director, Commercial Development, Lonza, said, “Increasing our capabilities by adding mid-scale API manufacturing at our site in Nansha will benefit our customers, and especially the many global emerging biotech companies we partner with. 3,5-Benzyliden-2-desoxy-D-ribose-diisopropylmercaptan vendor & factory Its approval has since been called into question, however, and the head of the FDA is now calling for a federal investigation looking into interactions between agency staff and the biotech company.,RELATED: With cost cuts and asset sales largely wrapped, Takeda gears up for growth: CEO
